Innovative hyaluronic acid (HA) treatments are revolutionizing the management of osteoarthritis (OA), offering patients effective relief and improved mobility. Viscosupplementation, the intra-articular injection of HA, plays a crucial role in reducing pain, enhancing joint function, and delaying surgical interventions, allowing individuals to maintain an active lifestyle for longer.

Osteoarthritis: A Growing Global Concern 

Osteoarthritis is the leading cause of musculoskeletal disability worldwide, placing an increasing burden on healthcare systems. Characterized by progressive cartilage deterioration and joint dysfunction, OA is set to become even more prevalent due to the aging population. Addressing this challenge requires innovative, non-invasive treatments that restore joint function and improve patient quality of life: this is the case of viscosupplementation with HA, which can counteract cartilage deficits, enhance the spontaneous repair processes and effectively control pain. 

IBSA’s Advanced Portfolio of HA-Based Solutions 

As a global leader in HA production through bio-fermentation, IBSA has developed two flagship viscosupplementation products for the management of osteoarthritis and musculoskeletal conditions: 

• SINOVIAL® HL pre-filled syringes: a next-generation intra-articular HA solution, designed to reduce pain, improve joint mobility, and minimize the need for rescue medication. Its efficacy is noticeable from the first injection and lasts up to six months, suggesting a long-lasting carry-over effect of the treatment. This characteristic reduces the frequency of procedures and lowers the risk of infection. 

• SINOGEL®: based on high molecular weight hyaluronic acid enriched with chondroitin – a natural component of connective tissues – in the highest percentage on the market, this innovative formulation naturally re-establishes the viscoelastic properties of synovial fluid, delivering faster pain relief and improved joint and tendon mobility. 

NAHYCO® HYBRID TECHNOLOGY: A Game Changer in HA Therapy 

Both SINOVIAL® HL and SINOGEL® are powered by IBSA’s patented NAHYCO® HYBRID TECHNOLOGY, which combines high and low molecular weight HA to optimize viscosity, elasticity, and resistance to degradation. This innovation, which allows the delivery of high quantities of HA, ensures enhanced joint lubrication while mimicking the physical and mechanical properties of synovial fluid, delivering long-lasting therapeutic benefits without compromising injection safety and ease of administration. 

With cutting-edge HA-based treatments, IBSA reaffirms its position as a leader in viscosupplementation, helping patients worldwide regain their quality of life and maintain an active lifestyle. 

— 

IBSA’s comprehensive portfolio covers 10 therapeutic areas, including prescription drugs, OTC medicines, medical devices, and food supplements. With state-of-the-art R&D centers and cutting-edge manufacturing facilities, the company continues to develop groundbreaking pharmaceutical solutions that meet the evolving needs of patients and healthcare professionals worldwide.